Benralizumab for the Prevention of COPD Exacerbations
Gerard J. Criner(Temple Lung Center), Ubaldo J. Martin(AstraZeneca (Japan)), Bartolomé R. Celli(St. Elizabeth's Medical Center), Alejandra Ramírez‐Venegas(Instituto Nacional de Enfermedades Respiratorias), Mona Bafadhel(National Institute for Health and Care Excellence), Natalya Makulova(AstraZeneca (Japan)), Alberto Papi(University of Ferrara), Sean O’Quinn(AstraZeneca (Japan)), Frank C. Sciurba(University of Pittsburgh), Don D. Sin(St. Paul's Hospital), Christopher E. Brightling(University of Leicester), Leif Bjermer(Lund University), Àlvar Agustí(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Claus Vogelmeier(German Center for Lung Research), Maria Jison(AstraZeneca (Japan)), Dave Singh(University of Manchester), Paul Newbold(AstraZeneca (Japan)), Vibeke Backer(Bispebjerg Hospital), Mitchell Goldman(AstraZeneca (Japan)), Vivian H. Shih(AstraZeneca (Japan)), Yu-Feng Wei(E-Da Hospital), Motokazu Kato(Kishiwada City Hospital)
Cited by 329
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
|American Journal of Respiratory and Critical Care Medicine|2017|3.2k
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
|New England Journal of Medicine|2010|3k
American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation
|American Journal of Respiratory and Critical Care Medicine|2006|2k
Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
|American Journal of Respiratory and Critical Care Medicine|2010|1k